+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Multi-component vaccine comprising at least three antigens to protect against disease cased by Haemophilus influenzae



Multi-component vaccine comprising at least three antigens to protect against disease cased by Haemophilus influenzae



Official Gazette of the United States Patent & Trademark Office Patents 1254(5), Jan 29



A multi-component immunogenic composition confers protection on an immunized host against infection caused by Haemophilus influenzae. Such composition comprises at least three different antigens of Haemophilus influenzae, two of which are adhesins. High molecular weight (HMW) proteins and Haemophilus influenzae adhesin (Hia) proteins of non-typeable Haemophilus influenzae comprise the adhesin components while the other antigen is a non-proteolytic analog of Hin47 protein. Each component does not impair the immunogenicity of the others. The Haemophilus vaccine may be combined with DTP component vaccines, which may contain inactivated poliovirus, including type 1, type 2 and/or type 3, and/or a conjugate of a capsular polysaccharide of Haemophilus influenzae and tetanus or diphtheria toxoid, including PRP-T, to provide a multi-valent component vaccine without impairment of the immunogenic properties of the other antigens.

(PDF emailed within 1 workday: $29.90)

Accession: 035349076

Download citation: RISBibTeXText


Related references

Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis. Official Gazette of the United States Patent & Trademark Office Patents 1258(3), May 21, 2002

Immunization with oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine on a large health maintenance organization population: extended follow-up and impact on Haemophilus influenzae disease epidemiology. The Kaiser Permanente Pediatric Vaccine Study Group. Pediatric Infectious Disease Journal 11(8): 610-613, 1992

Invasive disease due to Haemophilus influenzae serotype f: clinical and epidemiologic characteristics in the H. influenzae serotype b vaccine era. The Haemophilus influenzae Study Group. Clinical Infectious Diseases 22(6): 1069-1076, 1996

Methylase activities from Haemophilus influenzae that protect Haemophilus parainfluenzae transforming deoxyribonucleic acid from inactivation by Haemophilus influenzae endonuclease R. Journal of Bacteriology 123(1): 287-293, 1975

Supplement 1. Epidemiology, Pathogenesis, and Prevention of Haemophilus influenzae Disease || The P6 Outer Membrane Protein of Nontypeable Haemophilus influenzae as a Vaccine Antigen. Journal of Infectious Diseases 165: S203-S205, 1992

Supplement 1. Epidemiology, Pathogenesis, and Prevention of Haemophilus influenzae Disease || Maternal Immunization with the Capsular Polysaccharide Vaccine for Haemophilus influenzae Type b. Journal of Infectious Diseases 165: S134-S136, 1992

Supplement 1. Epidemiology, Pathogenesis, and Prevention of Haemophilus influenzae Disease || Respiratory Immunity Stimulated by Intestinal Immunization with Purified Nontypeable Haemophilus influenzae Antigens. Journal of Infectious Diseases 165: S199-S201, 1992

Invasive Haemophilus influenzae disease in a rural area since the introduction of the Haemophilus influenzae type B vaccine. Journal of Investigative Medicine 50(1): 127A, 2002

Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine and haemophilus influenzae type b capsular polysaccharide conjugate vaccine. Biologicals 27(2): 167-176, 1999

Supplement 1. Epidemiology, Pathogenesis, and Prevention of Haemophilus influenzae Disease || Safety, Immunogenicity, and Efficacy in Infancy of Oligosaccharide Conjugate Haemophilus influenzae Type b Vaccine in a United States Population: Possible Implications for Optimal Use. Journal of Infectious Diseases 165: S139-S143, 1992

Incidence of Haemophilus influenzae type b disease in The Gambia 14 years after introduction of routine Haemophilus influenzae type b conjugate vaccine immunization. Journal of Pediatrics 163(1 Suppl): S4-S7, 2013

Epidemiology of invasive Haemophilus influenzae type b disease among children in Finland before vaccination with Haemophilus influenzae type b conjugate vaccine. Pediatric Infectious Disease Journal 8(5): 297-302, 1989

Postlicensure surveillance for Haemophilus influenzae type b invasive disease after use of Haemophilus influenzae type b oligosaccharide CRM197 conjugate vaccine in a large defined United States population: a four-year eight-month follow-up. Pediatric Infectious Disease Journal 14(11): 978-981, 1995

Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in US children aged 18-59 months. Haemophilus Influenzae Vaccine Efficacy Study Group. Lancet 338(8764): 395-398, 1991

Non-type b Haemophilus influenzae disease: clinical and epidemiologic characteristics in the Haemophilus influenzae type b vaccine era. Pediatric Infectious Disease Journal 20(3): 300-305, 2001